Hing Sham Net Worth

The estimated Net Worth of Hing Sham is at least $6.73 Milion dollars as of 7 March 2018. Hing Sham owns over 10,714 units of Global Blood Therapeutics stock worth over $6,726,745 and over the last 9 years Hing sold GBT stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Hing Sham GBT stock SEC Form 4 insiders trading

Hing has made over 5 trades of the Global Blood Therapeutics stock since 2015, according to the Form 4 filled with the SEC. Most recently Hing exercised 10,714 units of GBT stock worth $5,250 on 7 March 2018.

The largest trade Hing's ever made was exercising 25,490 units of Global Blood Therapeutics stock on 17 August 2015 worth over $24,216. On average, Hing trades about 5,066 units every 58 days since 2015. As of 7 March 2018 Hing still owns at least 98,215 units of Global Blood Therapeutics stock.

You can see the complete history of Hing Sham stock trades at the bottom of the page.

What's Hing Sham's mailing address?

Hing's mailing address filed with the SEC is C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Global Blood Therapeutics

Over the last 9 years, insiders at Global Blood Therapeutics have traded over $164,753,446 worth of Global Blood Therapeutics stock and bought 255,000 units worth $8,595,265 . The most active insiders traders include Advisors Llcperceptive Life..., Rock Ventures Ii, L.P.Third... a Kevin P Starr. On average, Global Blood Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,133,144. The most recent stock trade was executed by Nazila Habibizad on 1 October 2022, trading 1,557 units of GBT stock currently worth $106,639.

What does Global Blood Therapeutics do?

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.

Complete history of Hing Sham stock trades at Global Blood Therapeutics

Global Blood Therapeutics executives and stock owners

Global Blood Therapeutics executives and other stock owners filed with the SEC include:

• Ted Love,
  President, Chief Executive Officer, Director
• Brian Cathers,
  Chief Scientific Officer
• Tricia Suvari,
  Chief Legal Officer
• Jung Choi,
  Chief Business and Strategy Officer
• David Johnson,
  Chief Commercial Officer
• Jeffrey Farrow,
  Chief Financial Officer
• Dr. Ted W. Love,
  Pres, CEO & Director
• Dr. Ted W. Love M.D.,
  Pres, CEO & Director
• David L. Johnson,
  Chief Commercial Officer
• Jeffrey S. Farrow,
  CFO & Principal Accounting Officer
• Jung E. Choi,
  Chief Bus. & Strategy Officer
• Dr. Kim Smith-Whitley M.D.,
  Exec. VP and Head of R&D
• Patricia Borga Suvari,
  Chief Legal Officer & Sec.
• Mark Perry,
  Lead Independent Director
• Scott Morrison,
  Independent Director
• Wendy Yarno,
  Independent Director
• Deval Patrick,
  Director
• Glenn Pierce,
  Independent Director
• Philip Pizzo,
  Independent Director
• Willie Brown,
  Independent Director
• Dawn Svoronos,
  Independent Director
• Eric Fink,
  Chief Human Resource Officer
• Stephanie Yao,
  Sr. Director of Corp. Communications & Investor Relations
• Nazila Habibizad,
  Exec. VP of Operations
• Dr. Andrej Sali Ph.D.,
  Founder & Advisor
• Dr. Matthew P. Jacobson Ph.D.,
  Founder & Advisor
• Dr. David R. Phillips,
  Founder & Advisor
• Lesley Ann Calhoun,
  See Remarks
• Rock Ventures Ii, L.P.Third...,
  
• Rock Ventures Ii, L.P.Third...,
  
• Michael W Bonney,
  Director
• Eleanor Ramos,
  Chief Medical Officer
• Kevin P Starr,
  Director
• Charles J Homcy,
  Director
• Robert I Tepper,
  10% owner
• Rock Ventures Ii, L.P.Starr...,
  
• Hing Sham,
  See Remarks
• Joshua Lehrer Graiwer,
  Chief Medical Officer
• Advisors Llcperceptive Life...,
  
• Peter Radovich,
  See Remarks
• Nazila Habibizad,
  See Remarks
• John Schembri,
  See Remarks
• Rock Ventures Ii, L.P.Third...,
  
• Rock Ventures Iii, L.P.Thir...,
  
• Carrie Krehlik,
  Chief Human Resources Officer
• Alexis A. Thompson,
  Director
• Kim Smith Whitley,
  See Remarks